CLINICAL_TRIALS
trial_result
· 2017-05-19
Clinical Trial Update: Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer [Phase 2]
Summary
Phase II trial of naltrexone in hormone-refractory metastatic breast cancer was terminated; results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-05-19